Fasiglifam

Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.

Product Specifications

CAS Number

[1000413-72-8]

Product Name Alternative

TAK-875

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Free Fatty Acid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/TAK-875.html

Purity

98.97

Solubility

DMSO : ≥ 128 mg/mL

Smiles

CC1=C(C(C)=CC(OCCCS(C)(=O)=O)=C1)C2=CC(COC3=CC=C4[C@@H](COC4=C3)CC(O)=O)=CC=C2

Molecular Formula

C29H32O7S

Molecular Weight

524.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Tsujihata Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.J Pharmacol Exp|[2]Yoshiyuki Tsujihata, et al. TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. JPET July 13, 2011|[3]Nagatake T, et al. 17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol. 2017 Dec 26. pii: S0091-6749 (17) 32949-4.|[4]Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875) -induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197.